Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(2), s4. https://doi.org/10.25251/skin.6.supp.4